期刊文献+

二氢吡啶类钙通道阻滞剂及其药物手性研究 被引量:5

Dihydropyridines Calcium Channel Blockers and Chiral Drugs Research
原文传递
导出
摘要 人体是一种高度复杂的手性环境。手性药物用于机体后,两对映体与体内的大分子物质结合,呈现作用机制和结合力的差别,从而导致手性药物的体内立体选择性特征,产生药理学上的差别。二氢吡啶类钙通道阻滞剂具有舒张血管等重要作用,在临床上对治疗高血压等心脑血管疾病具有很好的临床应用价值。本文就以手性药物和钙通道阻滞剂的药效学立体选择性作一综述。 The human body is a highly complex chiral environment. After chiral drugs affect the body, two enantiomers bound to macromolecular show differences in aspect of mechanism and integration, resulting in the stereoselectivity characteristics of the chiral drug and differences in pharmacology. Dihydropyridines (DHPs) calciumchannel blockers (CCBs), playing an important role in the relax- ation of blood vessel, have very good values in the clinical treatment of hypertension and other cardiovascular and cerebrovascular dis- eases. In this review the stereoselective pharmacodynamics of calciumchannel blockers and chiral drugs are summarized.
出处 《现代生物医学进展》 CAS 2009年第1期181-185,共5页 Progress in Modern Biomedicine
关键词 手性 手性药物 钙通道阻滞剂 立体选择性 chirality chiral drugs calciumchannelblocker stereoselective
  • 相关文献

参考文献30

  • 1Shen LL, Pemet AG. Mechanism of Inhibition of DNA Gyrase by Analogues of Nalidixic Acid: The Target of the Drugs is DNA [J]. Proc Natl Acad Sci USA, 1985,82:307
  • 2Li Gao. The stereoselective of cilnical pharmacokinetics in chiral drugs[J]. Chinese Journal of Hospital Pharmacy, 1999,19:429-431 (In Chinese)
  • 3De Camp WH. Chiral drugs: the FDA perspective on manufacturing and control [J]. J Pharm Biomed Anal, 1993,11,1167-72
  • 4Wang Dan, Li Ya, He Lang. The development and application of chiral drugs [J]. Modem medicine and public health, 2007, 23,837-8(In Chinese)
  • 5Arien EJ. Stereochemistry:a source of problems in medicinal chemistry[J]. Med Res Rev, 1986,6,451-66
  • 6Nerurkar SG, Dighe SV, Williams RL. Bioequivalence of racemic drugs [J]. J Clin Pharmacol, 1992,32,935-43
  • 7Bischer A, Zia-Amirhosseini P, Iwaki M, et al. Stereoselective binding properties of naproxen glucuronide diastereomers to proteins [J]. J Pharmacokinet Biopharm, 1995, 23,379 -95
  • 8Carter RB, Dykstra LA. Effects of picenadol (LY150720)and its stereoisomers on electric shock titration in the squirrel monkey [J]. J Pharmacol Exp Ther,1985,234,299-306
  • 9Middlefell VC, Price TL. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret[J]. Br J Pharmacol, 1991, 103,1011-2
  • 10Tabi T, Magyar K, Szoko E. Chiral characterization of deprenyl- N-oxide and other deprenyl metabolitesby capillary electrophoresis using a dual cyclodextrin system in rat urine [J]. Electrophoresis, 2003, 24, 2665-73

同被引文献74

  • 1王晋,张汝华,孙淑英.尼莫地平多晶型的研究[J].药学学报,1995,30(6):443-448. 被引量:27
  • 2蔡德山.2004年抗高血压钙拮抗剂药物市场状况[J].上海医药,2005,26(9):421-425. 被引量:2
  • 3尤启冬,林国强.手性药物研究与应用.北京:化学工业出版社,2003.
  • 4Dalgliesh CE. The optical resolution of aromatic amino acids on paper chromatograms. J Chem Soc.1952, 3940-3952.
  • 5Rahman N,Azmi SNH. Spectrophotometric method for the deter- mination of amlodipine besylate with ninhydrin in drug formula- tions [J]. ]I Famlaco, 2001,56(10) :731 -735.
  • 6Rosenthal T, Gavras I. Fixed - drug combinations as first - line treatment for hypertension [ J]. Progress in Cardiovascu|ar Disea- ses, 2006, 48(6) :416 -425.
  • 7Siddiqui MA, Plosker GL. Fixed - dose combination enalapril/nit- rendipine: A review of its use in mild - to - moderate hyperten- sion [ J]. Drugs,2004,64 : 1135 - 1148.
  • 8Hantzsch, A. Chem. Ber. 1881, 14 (2), 1637. doi: 10.1002/cber.18810140214.
  • 9Goldmann, S.; Stoltefuss, J. Angew. Chem. Int. Edit. Engl. 1991, 30 (12), 1559-1578. doi: 10.1002/anie.199115591.
  • 10Triggle, D. J. Cell. Mol. Neurobiol. 2003, 23 (3), 293.doi: 10.1023/A:1023632419813.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部